378 related articles for article (PubMed ID: 31445345)
21. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
22. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
23. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
Moore N; Verdoux H; Fantino B
Int Clin Psychopharmacol; 2005 May; 20(3):131-7. PubMed ID: 15812262
[TBL] [Abstract][Full Text] [Related]
24. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
25. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
26. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
27. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
[TBL] [Abstract][Full Text] [Related]
28. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
Kornstein SG; Li D; Mao Y; Larsson S; Andersen HF; Papakostas GI
CNS Spectr; 2009 Jun; 14(6):326-33. PubMed ID: 19668123
[TBL] [Abstract][Full Text] [Related]
29. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study].
Schmitt L; Arbus C; Tonnoir B
Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629
[TBL] [Abstract][Full Text] [Related]
30. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
Lepola U; Wade A; Andersen HF
Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
[TBL] [Abstract][Full Text] [Related]
31. Escitalopram in the long-term treatment of major depressive disorder.
Wade A; Despiegel N; Heldbo Reines E
Ann Clin Psychiatry; 2006; 18(2):83-9. PubMed ID: 16754413
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study.
Wade AG; Crawford GM; Yellowlees A
BMC Psychiatry; 2011 Mar; 11():42. PubMed ID: 21410960
[TBL] [Abstract][Full Text] [Related]
33. Pre-treatment factor structures of the Montgomery and Åsberg Depression Rating scale as predictors of response to escitalopram in Indian patients with non-psychotic major depressive disorder.
Basu A; Chadda R; Sood M; Rizwan SA
Asian J Psychiatr; 2017 Aug; 28():154-159. PubMed ID: 28784374
[TBL] [Abstract][Full Text] [Related]
34. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Lepola UM; Loft H; Reines EH
Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155
[TBL] [Abstract][Full Text] [Related]
35. [Escitalopram versus serotonin reuptake inhibitors].
Millet B
Encephale; 2008 Jun; 34(3):280-3. PubMed ID: 18558150
[TBL] [Abstract][Full Text] [Related]
36. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
Kennedy SH; Andersen HF; Thase ME
Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
[TBL] [Abstract][Full Text] [Related]
37. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial.
Talaei A; Hassanpour Moghadam M; Sajadi Tabassi SA; Mohajeri SA
J Affect Disord; 2015 Mar; 174():51-6. PubMed ID: 25484177
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison.
Matreja PS; Badyal DK; Khosla P; Deswal RS
Hum Psychopharmacol; 2007 Oct; 22(7):477-82. PubMed ID: 17647298
[TBL] [Abstract][Full Text] [Related]
40. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
